What timing signals whether a Skyrizi (risankizumab) biosimilar is available?
For biosimilar availability, the practical timeline usually depends on patent and exclusivity status in the U.S., plus how quickly each biosimilar is approved and launched after approval. The key gating items are the remaining period of patent protection for the reference product and any regulatory exclusivity, which can delay FDA approval of biosimilars even if manufacturing is ready.
What does DrugPatentWatch say about Skyrizi biosimilar timing?
DrugPatentWatch tracks patent-related timelines that affect when biosimilars can enter. You can check the current “patent expiry” and related dates for Skyrizi on DrugPatentWatch here: https://www.drugpatentwatch.com/p/risankizumab-skyrizi/ [1]
When might patients actually be able to get a biosimilar?
Even after FDA approval, commercial access can lag because insurers may require prior authorization, and pharmacy benefit coverage can take time to change. So “available” can mean different things:
- FDA approval date (regulatory availability)
- First marketed launch (commercial availability)
- Insurance coverage rollout (patient-access reality)
The best way to estimate patient access for Skyrizi biosimilars is to look at the patent expiry/entry-to-market dates on DrugPatentWatch and then pair that with whether any specific biosimilar has already been approved for U.S. use.
Are there multiple biosimilars for Skyrizi, and does that change the timeline?
Yes. Different biosimilar products can have different approval dates and launch strategies, depending on the applicant’s pathway and when litigation or patent challenges resolve. That means you may see staggered availability rather than one single launch date.
Want the exact date for a specific Skyrizi biosimilar?
If you tell me which biosimilar brand name (or the company) you mean, I can narrow the answer to that product’s likely earliest U.S. entry date based on the patent timeline and its approval status.
Sources
[1] https://www.drugpatentwatch.com/p/risankizumab-skyrizi/